Can-Fite BioPharma Shares Surge 55.9% on Trial Success and $8 Target
CANF•Can-Fite BioPharma's Namodenoson achieved its primary safety endpoint in a Phase 2a pancreatic cancer trial and secured a Japanese patent for its anti-obesity technology. H.C. Wainwright raised the price target to $8, implying a 72.8% upside, while shares jumped 55.9% on record 57 million volume.
1. Price Target Raises Upside Potential
H.C. Wainwright set an $8 price target for Can-Fite BioPharma shares, implying a 72.8% increase from its last closing price of $4.63 and signaling strong analyst confidence in the company's pipeline.
2. Phase 2a Trial Achieves Safety Milestone
The Namodenoson pancreatic cancer study met its primary safety endpoint in Phase 2a, with the drug well-tolerated and one second-line patient surviving over 18 months, underscoring a favorable risk profile.
3. Japanese Patent Strengthens IP Portfolio
Can-Fite BioPharma secured a patent in Japan for Namodenoson's anti-obesity technology, extending exclusive rights in a key pharmaceutical market and bolstering the company's competitive positioning.
4. Shares Surge on Volume Spike
Shares jumped 55.89% on July 2, with trading volume exceeding 57.03 million shares, driving the market capitalization to roughly $2.49 million and reflecting heightened investor interest.
